PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Research and Development, IncellDx Inc, San Carlos, CA, United States.\', \'Department of Anesthesia, Lawrence General Hospital, Lawrence, MA, United States.\', \'Department of Molecular Diagnostics, Bio-Rad Laboratories, Hercules, CA, United States.\', \'Department of Allergy and Immunology, New York University (NYU) Langone Health, New York, NY, United States.\', \'Lab of Tumor Chemosensitivity, Research Center on Tropical Diseases (CIET)/Research Center on Surggery and Cancer (DC) Lab, Faculty of Microbiology, Universidad de Costa Rica, San Jose, Costa Rica.\', \'Department of Computer Science and Informatics (ECCI), Universidad de Costa Rica, San Jose, Costa Rica.\', \'Department of Molecular Biology, Avrok Laboratories, Inc., Azusa, CA, United States.\', \'Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR, United States.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.3389/fimmu.2021.746021
?:doi
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 35082777
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
is ?:relation_isRelatedTo_publication of
?:title
  • Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35082777>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35082777>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all